Esketamine nasal spray shows greater improvement in health-related quality of life over 32 weeks versus quetiapine extended release in patients with treatment resistant depression by A. H. Young, B. T. Baune, N. Cardoner, R. Frey, T. Ito, Y. Kambarov, A. Lacerda, B. Rive, C. von Holt, A. J. Oliveira-Maia

Get full text